ImExHS Limited (AU:IME)
ASX:IME
Want to see AU:IME full AI Analyst Report?
Top Page
ImExHS Limited
(Sydney:IME)
Select Model
Select Model
Rating:51Neutral
Price Target:
AU$0.35
â–¼(-12.00% Downside)
Action:Reiterated
Date:03/27/26
The score is primarily driven by mixed financial performance: accelerating revenue growth and a low-debt balance sheet are positives, but ongoing losses, negative returns, and weakened gross margin are significant headwinds. Technical indicators point to soft near-term momentum, and valuation is constrained by negative earnings and no dividend support.
Positive Factors
Recurring SaaS & AI platform
ImExHS’s Hiruko cloud AI platform and subscription licensing create recurring revenue and multi-year contracts. This business model drives predictable renewal cash, supports customer stickiness and upsell potential, and aligns with long-term healthcare digitization and AI adoption trends.
Negative Factors
Persistent Losses
Ongoing net losses and negative operating margins limit the company’s ability to self-fund growth and R&D. Persistent unprofitability raises the need for external capital, increases dilution risk, and weakens long-term return prospects unless margins sustainably improve.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring SaaS & AI platform
ImExHS’s Hiruko cloud AI platform and subscription licensing create recurring revenue and multi-year contracts. This business model drives predictable renewal cash, supports customer stickiness and upsell potential, and aligns with long-term healthcare digitization and AI adoption trends.
Read all positive factors
ImExHS Limited (IME) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$19.03M
Dividend YieldN/A
Average Volume (3M)41.77K
Price to Earnings (P/E)―
Beta (1Y)0.24
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
Employees400
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.06
Shares Outstanding54,375,668
10 Day Avg. Volume23,052
30 Day Avg. Volume41,775
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)1.29
Price to Sales (P/S)0.71
P/FCF Ratio83.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)AU$32.59M
ImExHS Limited Business Overview & Revenue Model
Company Description
ImExHS Limited delivers cloud-powered medical imaging technologies to customers worldwide, including those in Australia. The firm specializes in the development and sale of modular imaging software systems, which encompass comprehensive informatio...
How the Company Makes Money
ImExHS Limited generates revenue primarily through the sale and licensing of its proprietary software solutions, including subscription-based models for its Hirukoâ„¢ platform. The company charges healthcare providers, hospitals, and pathology labs ...
ImExHS Limited Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
74
Positive
Cash Flow
52
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 28.97M | 26.57M | 19.67M | 17.12M | 13.37M |
| Gross Profit | 8.31M | 11.03M | 3.50M | 3.52M | 5.22M |
| EBITDA | 1.52M | 45.58K | -1.26M | -744.21K | -3.00M |
| Net Income | -2.88M | -2.63M | -4.19M | -3.04M | -4.70M |
Balance Sheet | |||||
| Total Assets | 23.73M | 21.81M | 22.65M | 20.99M | 25.01M |
| Cash, Cash Equivalents and Short-Term Investments | 3.30M | 2.07M | 2.36M | 1.91M | 4.19M |
| Total Debt | 566.32K | 1.19M | 1.29M | 1.12M | 2.40M |
| Total Liabilities | 7.86M | 7.33M | 6.67M | 5.09M | 8.36M |
| Stockholders Equity | 15.87M | 14.47M | 15.98M | 15.90M | 16.65M |
Cash Flow | |||||
| Free Cash Flow | 244.16K | -1.69M | 414.59K | -4.23M | -5.53M |
| Operating Cash Flow | 564.71K | -634.68K | 2.61M | -2.20M | -2.97M |
| Investing Cash Flow | -1.19M | -765.91K | -2.13M | -2.22M | -3.39M |
| Financing Cash Flow | 1.68M | 1.18M | -98.61K | 2.25M | -161.78K |
ImExHS Limited Technical Analysis
Negative
0.40
Price Trends
0.38
Negative
0.40
Negative
0.34
Positive
Market Momentum
>-0.01
Negative
36.81
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IME, the sentiment is Negative. The current price of 0.4 is above the 20-day moving average (MA) of 0.36, above the 50-day MA of 0.38, and above the 200-day MA of 0.34, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 36.81 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IME.
ImExHS Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$19.08M | 26.43 | 7.57% | ― | 31.36% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$19.03M | -6.56 | -19.01% | ― | ― | ― | |
44 Neutral | AU$27.03M | -4.78 | -14.19% | ― | 0.03% | -5.85% | |
43 Neutral | AU$68.10M | -8.95 | -59.96% | ― | ― | ― | |
43 Neutral | AU$27.17M | -3.94 | -1009.84% | ― | 13.69% | 7.57% |
* Healthcare Sector Average
AU:IME
ImExHS Limited
0.35
0.02
6.06%
AU:RHT
Resonance Health Ltd
0.04
>-0.01
-6.98%
AU:BMT
Beamtree Holdings Ltd
0.09
-0.21
-69.00%
AU:SHG
Singular Health Group Ltd
0.22
-0.18
-44.87%
AU:PCK
PainChek Ltd
0.13
-0.26
-66.67%
ImExHS Limited Corporate Events
ImExHS boosts CEO equity stake with new option grants
Jun 2, 2026
ImExHS Limited has updated the market on changes to CEO and director Germán Arango’s interests, following the grant of a substantial package of share options. The new awards comprise salary-sacrifice options, short-term incentive option...
ImExHS Director Increases Shareholding Through Fee-for-Shares Arrangement
Jun 2, 2026
ImExHS Limited has disclosed a change in the interests of director Carlos Jaime Palacio, who has increased his direct holding by 60,988 fully paid ordinary shares. The new shares were issued in lieu of non-executive director fees for the March and...
ImExHS director boosts shareholding through fee-for-equity arrangement
Jun 2, 2026
ImExHS Limited has disclosed a change in the holdings of non-executive director Douglas Lingard, who increased his direct stake in the company through an issue of ordinary shares. He received 60,988 fully paid ordinary shares, lifting his direct h...
ImExHS Director Douglas Flynn Increases Stake Through Fee-for-Shares Arrangement
Jun 2, 2026
ImExHS Limited has disclosed a change in the interests of non-executive director Douglas Flynn, who has received 121,976 fully paid ordinary shares directly in the company. The shares, valued at $50,000 and priced at $0.4099 each, were issued in l...
ImExHS Director Increases Shareholding Through Fee-for-Equity Arrangement
Jun 2, 2026
ImExHS Limited has disclosed a change in director Damian Banks’ interests, with the non-executive director receiving 60,988 fully paid ordinary shares issued in lieu of cash fees for the March and June 2026 quarters. The issuance, valued at ...
ImExHS Seeks ASX Quotation for New Employee Incentive Shares
Jun 1, 2026
ImExHS Limited has applied for quotation on the ASX of 304,940 new ordinary fully paid shares, to be issued on 1 June 2026 under its employee incentive arrangements. The move modestly expands the company’s quoted capital base and reflects on...
ImExHS Grants Unquoted CEO Salary Sacrifice Options
Jun 1, 2026
ImExHS Limited has issued 266,438 unquoted CEO Salary Sacrifice Options as part of its executive remuneration arrangements, effective 1 June 2026. The move reinforces the company’s use of equity-based compensation to align leadership incenti...
ImExHS Grants 2026 Incentive Options to CEO and Staff
Jun 1, 2026
ImExHS Limited has notified the market of the issue of 182,965 unquoted options to its chief executive and employees as part of its 2026 short term incentive payment plan. The options, issued on 1 June 2026, represent an equity based reward design...
IMEXHS Names New CFO as Finance Team Strengthened Across Regions
Jun 1, 2026
IMEXHS Limited has announced that Fabio Carrillo will be appointed Chief Financial Officer from 1 August 2026, while continuing his role as a director at Crofts CA, with support from a strengthened finance team in Colombia and Crofts CA. Carrillo,...
IMEXHS wins major AI-enabled radiology tender in Mexico
May 25, 2026
IMEXHS Limited, an ASX-listed medical imaging software and radiology services group, develops cloud-based, vendor-neutral SaaS platforms such as PACS, RIS, CIS and pathology information systems for hospitals and clinics across 18 countries. Its sc...
ImExHS Director Douglas Flynn Restructures Indirect Shareholdings
May 7, 2026
ImExHS Limited has reported a change in the interests of director Douglas Flynn, detailing an internal reorganisation of his indirect holdings in the company’s shares. The transaction involved an off-market sale of 2,181,418 fully paid ordin...
ImExHS lifts Q1 earnings as AI-driven radiology strategy accelerates
Apr 30, 2026
ImExHS Limited reported a strong start to FY26, with first-quarter revenue rising 13% year-on-year to $7.9 million and underlying EBITDA improving to $0.8 million, supported by annual recurring revenue of $34.8 million and stable debt levels. The ...
ImExHS rolls out AI-native agentic platform to automate radiology workflows
Apr 28, 2026
ImExHS Limited has launched an AI-native, agentic platform for radiology by embedding five proprietary AI agents across its Aquila+ RIS/PACS workflow, from appointment scheduling to final report delivery. Two agents are already live for clients, o...
ImExHS Sets Hybrid AGM for May as It Formalises Digital Governance Approach
Apr 17, 2026
ImExHS Limited has called its Annual General Meeting for 11:00am AEST on 20 May 2026, to be held as a hybrid event at its Sydney CBD venue and via an online platform operated by Automic, allowing shareholders to attend, vote, and ask questions eit...
ImExHS Director Updates Equity Interests After Option Lapse
Apr 8, 2026
ImExHS Limited has reported a change in the securities held by director German Arango, detailing the lapse of certain option holdings after vesting conditions were not met. Following the change, Arango retains substantial interests in the company ...
ImExHS Director Increases Direct Shareholding Through Option Exercise
Apr 8, 2026
ImExHS director Douglas Lingard has adjusted his holdings in the company following the exercise of nil‑price options into fully paid ordinary shares. He converted 20,044 options into the same number of shares at no cash consideration, increa...
ImExHS Options Lapse Cuts Potential Future Dilution
Apr 7, 2026
ImExHS Limited has notified the market of the cessation of several tranches of options after the conditions attached to these securities were not met by the specified dates. A total of 1,010,843 options across three series, all with nil exercise p...
ImExHS Seeks Quotation for Additional Ordinary Shares on ASX
Apr 7, 2026
ImExHS Limited has applied for quotation on the ASX of 20,044 additional ordinary fully paid shares, to be issued on 7 April 2026. The new securities arise from the exercise or conversion of existing options or other convertible instruments, margi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.